

WHAT IS CLAIMED IS:

- 5 1. A method for modulating migration of a cell that expresses a galectin-3 receptor comprising contacting the cell with a migration-modulating amount of galectin-3, galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
2. A method for modulating monocyte, neutrophil or macrophage migration comprising contacting a monocyte, neutrophil or macrophage with a migration-modulating amount of galectin-3, galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
3. The method of claim 1 or 2, wherein the migration is stimulated.
- 10 4. The method of claim 1 or 2, wherein the migration is inhibited.
5. The method of claim 1 or 2, wherein the galectin-3 comprises an N-terminal or C-terminal subsequence of galectin-3.
6. The method of claim 1 or 2, wherein the galectin-3 binding polypeptide comprises a galectin-3 antibody or a binding fragment thereof.
- 15 7. The method of claim 1 or 2, wherein the migration is modulated in an animal.
8. A method for increasing migration of monocytes, neutrophils or macrophages to an inflammatory site comprising contacting the inflammatory site with a migration-increasing amount of galectin-3, galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
- 20 9. A method for increasing migration of monocytes, neutrophils or macrophages to a site of infection comprising contacting the infection site with a migration-increasing amount of galectin-3, galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
- 25 10. A method for increasing migration of monocytes, neutrophils or macrophages to a tumor comprising contacting the tumor with a migration-increasing amount of galectin-3, galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
11. A method for decreasing migration of monocytes, neutrophils or macrophages to an inflammatory site comprising contacting the inflammatory site with a migration-increasing amount of galectin-3, galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
- 30 12. A method for decreasing migration of monocytes, neutrophils or macrophages to a site of infection comprising contacting the infection site with a migration-increasing amount of galectin-3, galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
- 35 13. A method for decreasing migration of monocytes, neutrophils or macrophages to a tumor comprising contacting the tumor with a migration-increasing amount of galectin-3, galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
14. A method for indentifying an agent that modulates galectin-3 mediated cell migration comprising:
contacting galectin-3 with a test agent; and
detecting galectin-3 mediated cell migration,

wherein an alteration of galectin-3 mediated cell migration in the presence of the test agent identifies an agent that modulates galectin-3 mediated cell migration.

15. The method of claim 14, wherein the agent increases galectin-3 mediated migration.

16. The method of claim 14, wherein the agent decreases galectin-3 mediated migration.

5 17. The method of claim 14, wherein the agent is a small molecule.

18. The method of claim 14, wherein the contacting is *in vitro*, intracellular, or *in vivo*.

19. A composition comprising an agent identified according to the method of claim 14.

20. The composition of claim 19, wherein the agent is a saccharide.

10 21. The composition of claim 20, wherein the saccharide is lactose, galactose, beta-galactoside, or an analog or derivative thereof.

22. The composition of claim 19, wherein the composition further comprises a drug.

23. A composition comprising a migration-modulating amount of an antibody that specifically binds galectin-3 and a suitable carrier, excipient or diluent.

15 24. A composition comprising a migration-modulating amount of an antibody that specifically binds galectin-3 and a drug.

25. A composition comprising a migration-modulating amount of galectin-3 or a functional subsequence thereof and a pharmaceutically acceptable carrier, excipient or diluent.

26. The composition of claim 25, wherein the composition further comprises a drug.

20 27. The composition of claim 22, or 24, or 26, wherein the drug is an anti-tumor, antiviral, antibacterial, anti-mycobacterial, anti-fungal, anti-cell proliferative or apoptotic agent.

28. A composition comprising galectin-3 or a functional subsequence thereof and an article of manufacture.

29. The composition of claim 28, wherein the article of manufacture comprises a dressing.

25 30. The composition of claim 29, wherein the dressing comprises a bandage, a suture, a sponge, or a surgical dressing.

31. A microfabricated device containing galectin-3 or a functional subsequence thereof in a pharmaceutically acceptable carrier, said device capable of controlled delivery of the galectin-3 or the functional subsequence.

32. The device of claim 31, wherein the device can be implanted in the body of a subject.

30 33. The device of claim 32, wherein the implantation site is a site of infection.

34. The device of claim 32, wherein the implantation site is in close proximity to or within a solid tumor.

35. The device of claim 32, wherein the implantation site is a site of a lesion.

50134006v3